Ryuya Yamanaka

Summary

Affiliation: Niigata University
Country: Japan

Publications

  1. ncbi Novel immunotherapeutic approaches to glioma
    Ryuya Yamanaka
    Niigata University, Brain Research Institute, Department of Neurosurgery, Asahimachi dori 1 757, Niigata City 951 8585, Japan
    Curr Opin Mol Ther 8:46-51. 2006
  2. ncbi Identification of expressed genes characterizing long-term survival in malignant glioma patients
    R Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata City, Japan
    Oncogene 25:5994-6002. 2006
  3. ncbi Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City, 951 8585, Japan
    J Neurooncol 72:107-13. 2005
  4. ncbi Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951 8585, Japan
    DNA Cell Biol 24:317-24. 2005
  5. ncbi Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City, 951 8585, Japan
    Ann Hematol 84:447-55. 2005
  6. ncbi Gene therapy of brain tumor with endostatin
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata City, Japan
    Drugs Today (Barc) 40:931-4. 2004
  7. ncbi Advances for the treatment of primary central nervous system lymphoma (review)
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City 951 8585, Japan
    Oncol Rep 12:563-8. 2004
  8. ncbi Alphavirus vectors for cancer gene therapy (review)
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata City, Japan
    Int J Oncol 24:919-23. 2004
  9. ncbi Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
    R Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City, 951 8585, Japan
    Br J Cancer 89:1172-9. 2003
  10. ncbi Results of treatment of 112 cases of primary CNS lymphoma
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
    Jpn J Clin Oncol 38:373-80. 2008

Collaborators

Detail Information

Publications39

  1. ncbi Novel immunotherapeutic approaches to glioma
    Ryuya Yamanaka
    Niigata University, Brain Research Institute, Department of Neurosurgery, Asahimachi dori 1 757, Niigata City 951 8585, Japan
    Curr Opin Mol Ther 8:46-51. 2006
    ..Biotherapy for malignant glioma with dendritic cells and peptides represents a novel treatment paradigm...
  2. ncbi Identification of expressed genes characterizing long-term survival in malignant glioma patients
    R Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata City, Japan
    Oncogene 25:5994-6002. 2006
    ..Our method was effective at classifying high-grade gliomas objectively, and provided a more accurate predictor of prognosis than histological grading...
  3. ncbi Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City, 951 8585, Japan
    J Neurooncol 72:107-13. 2005
    ..DCs loaded with total tumor lysate and IL-18 may represent a method for inducing Th1 immunoresponses against the entire repertoire of glioma antigens...
  4. ncbi Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951 8585, Japan
    DNA Cell Biol 24:317-24. 2005
    ..Thus, the Sindbis DNA system may represent a novel approach for the treatment of malignant brain tumors...
  5. ncbi Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City, 951 8585, Japan
    Ann Hematol 84:447-55. 2005
    ..Maintaining the dose of methotrexate while adding chemotherapeutic agents improved disease control and overall survival in patients with PCNSL, but early toxicity and delayed neurotoxicity are still a risk of this approach...
  6. ncbi Gene therapy of brain tumor with endostatin
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata City, Japan
    Drugs Today (Barc) 40:931-4. 2004
    ..Gene therapy with endostatin delivered via Semliki Forest virus may be a candidate for the development of a new treatment for brain tumors...
  7. ncbi Advances for the treatment of primary central nervous system lymphoma (review)
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City 951 8585, Japan
    Oncol Rep 12:563-8. 2004
    ..The well-designed, multicenter and randomized trials will elucidate the issues, such as best chemotherapy regimen, no brain irradiation in responder and second-line treatment...
  8. ncbi Alphavirus vectors for cancer gene therapy (review)
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata City, Japan
    Int J Oncol 24:919-23. 2004
    ..Alphavirus vectors demonstrate promise for the safe tumor-killing and tumor-specific immune responses. Recombinant alphavirus RNA replicons may facilitate gene therapy of cancer...
  9. ncbi Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
    R Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City, 951 8585, Japan
    Br J Cancer 89:1172-9. 2003
    ..This study demonstrated the safety and antitumour effects of autologous tumour lysate-pulsed dendritic cell therapy for patients with malignant glioma...
  10. ncbi Results of treatment of 112 cases of primary CNS lymphoma
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
    Jpn J Clin Oncol 38:373-80. 2008
    ..Due to the lack of well-conducted randomized trials, the optimal treatment remains controversial. Available retrospective studies are difficult to discuss, however, some common themes can be found...
  11. ncbi Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata
    Leuk Lymphoma 48:1119-26. 2007
    ..Additional treatment with a ProMACE-MOPP hybrid regimen is still effective for relapsed disease...
  12. ncbi Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients
    Masakazu Sano
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan
    Oncol Rep 16:1093-8. 2006
    ..These data suggest that increased expression of ECT2 contribute to promotion of tumor invasiveness and progression, implying that evaluation of ECT2 expression is a prognostic marker for glioma patients...
  13. ncbi Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University School of Medicine, Niigata University, Niigata, Japan
    Clin Cancer Res 11:4160-7. 2005
    ..To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent malignant glioma...
  14. ncbi Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma
    Tsutomu Kobayashi
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, Niigata City 951-8585, Japan
    Cancer Immunol Immunother 52:632-7. 2003
    ..DCs transfected with total tumor RNA may represent a method for inducing immune responses against the entire repertoire of glioma antigens...
  15. ncbi [Analysis of gene expression profiles in malignant brain tumors with respect to sensitivity to therapies]
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Reseach Instiute, Niigata University
    Nippon Rinsho 63:49-54. 2005
  16. ncbi Increased expression of CCAAT/enhancer binding protein beta correlates with prognosis in glioma patients
    Jumpei Homma
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951 8585, Japan
    Oncol Rep 15:595-601. 2006
    ..The data imply that the comparison of C/EBP beta expression could be a prognostic marker for patients with glioma...
  17. ncbi Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients
    Nobuyuki Genkai
    Department of Neurosurgery, Brain Research Institute, Niigata University, 1 757 Asahimachi dori, Niigata 951 8585, Japan
    Oncol Rep 15:1569-74. 2006
    ..These data suggest that increased expression of PTTG1 contributes to the tumorigenicity of glioma cells and may be useful as a prognostic marker for glioma patients...
  18. ncbi Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata City 951-8122, Japan
    Int J Oncol 23:913-23. 2003
    ....
  19. ncbi Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma
    Naoki Yajima
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
    Clin Cancer Res 11:5900-11. 2005
    ..CONCLUSIONS: Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients...
  20. ncbi [CTL precursor-oriented peptide vaccine therapy for malignant glioma]
    Naoki Yajima
    Department of Neurosurgery, Brain Research Institue, Niigata University
    Nippon Rinsho 63:582-7. 2005
  21. ncbi Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines
    Naoto Tsuchiya
    Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan
    Int J Oncol 27:1231-9. 2005
    ..Moreover, LCA lectin inhibited proliferation of glioma cells through induction of apoptosis. A2G2F on glioma specimens may provide a novel marker and target for the diagnosis and treatment of glioblastoma, respectively...
  22. ncbi [Dendritic cell therapy for malignant glioma]
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi-dori, Niigata 951-8585, Japan
    No To Shinkei 55:771-80. 2003
    ..The development of methods for manipulating dendritic cells for the purpose of vaccination will enhance the clinical usefulness of these cells for biotherapy for malignant glioma...
  23. ncbi Dendritic cell-based glioma immunotherapy (review)
    Ryuya Yamanaka
    Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi dori 1 757, Niigata City 951 8585, Japan
    Int J Oncol 23:5-15. 2003
    ..The development of methods for manipulating dendritic cells for the purpose of vaccination will enhance the clinical usefulness of these cells for biotherapy for malignant glioma...
  24. ncbi Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients
    Atsushi Kawaguchi
    Department of Neurosurgery, Niigata University, Kyoto, Japan
    Int J Oncol 40:721-30. 2012
    ....
  25. ncbi Immunohistochemical analysis of myelination following hemicranial irradiation in neonatal rats
    Gen Sato
    Department of Neurosurgery, Brain Research Institute, Niigata University, 1 757 Asahimachi dori, Niigata 951 8585, Japan
    Neurosci Lett 353:131-4. 2003
    ..These results show that myelination in the neonatal rat can recover from the developmental delay caused by a single 15 Gy dose of hemicranial irradiation...
  26. ncbi Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients
    Mingyue Jin
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka 830 0011, Japan
    Cancer Sci 99:1656-62. 2008
    ..g. lung, colon, stomach, liver and pancreatic) cells. Taken together, the two peptides derived from EphB6v might be appropriate targets for peptide-based specific immunotherapy for HLA-A2(+) patients with various cancers...
  27. ncbi Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients
    Mingyue Jin
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka 830 0011, Japan
    Oncol Rep 19:1277-83. 2008
    ..Taken together, the two peptides derived from the variant of EphB6 might be appropriate targets for peptide-based specific immunotherapy to HLA-A24(+) patients with malignant glioma...
  28. ncbi Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA
    Ryuya Yamanaka
    Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Neurosurg 97:1184-90. 2002
    ..Immunogene therapy for malignant gliomas was further investigated in this study to improve its therapeutic efficacy...
  29. ncbi Cell- and peptide-based immunotherapeutic approaches for glioma
    Ryuya Yamanaka
    Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka 830 0011, Japan
    Trends Mol Med 14:228-35. 2008
    ..Here, we review recent advances in DC- and peptide-based immunotherapy approaches for patients with gliomas...
  30. ncbi Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study
    Ryuya Yamanaka
    Leuk Lymphoma 48:1429-33. 2007
  31. ncbi Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12
    Ryuya Yamanaka
    Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Neurosurg 99:746-53. 2003
    ..The aim of this study was to investigate further immunogene treatment of malignant brain tumor to improve its therapeutic efficacy...
  32. ncbi Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report
    Ryuya Yamanaka
    Leuk Lymphoma 48:1019-22. 2007
  33. ncbi Peptide-based immunotherapeutic approaches to glioma: a review
    Ryuya Yamanaka
    Kurume University School of Medicine, Research Center of Innovative Cancer Therapy, Asahimachi 67, Kurume, Fukuoka 830 0011, Japan
    Expert Opin Biol Ther 7:645-9. 2007
    ..Now, peptide-based immunotherapy could be a new treatment modality for patients with brain tumors...
  34. ncbi [Peptide vaccination therapy for malignant glioma]
    Ryuya Yamanaka
    Research Center of Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830 0011, Japan
    Brain Nerve 59:251-61. 2007
    ..Peptide-based therapy of glioma seems to be safe and without major side effects. Biotherapy for malignant glioma with peptide will open a novel reality now...
  35. ncbi Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients
    Mamoru Harada
    Department of Immunology, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Oncol Rep 17:629-36. 2007
    ..These results suggest the existence of KIF-reactive CTL precursors in glioma patients, and should facilitate the development of specific immunotherapies for malignant glioma...
  36. ncbi Development of improved Sindbis virus-based DNA expression vector
    Ryuya Yamanaka
    Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    DNA Cell Biol 23:75-80. 2004
    ..We have demonstrated a high-level expression of the exogenous beta-galactosidase gene from the pSin-SV40-HDV-SV40pA construct using a Sindbis replication system...
  37. ncbi Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12
    Ryuya Yamanaka
    Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Neurosurg 97:611-8. 2002
    ..The authors evaluated dendritic cell (DC)-based immunotherapy for malignant brain tumor to improve its therapeutic efficacy...
  38. ncbi Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system
    Jie Li
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    J Neurosurg 109:536-46. 2008
    ....
  39. ncbi EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line
    Junya Fukai
    Department of Neurological Surgery, Wakayama Medical University, Wakayama, Japan
    Mol Cancer Ther 7:2768-78. 2008
    ..Thus, our results indicate that EphA4 plays an important role in malignant phenotypes of glioblastoma by enhancing cell proliferation and migration through accelerating a canonical FGFR signaling pathway...